Page 192 - Haematologica Vol. 109 - July 2024

ARTICLE - Disease burden of idiopathic MCD
M. Sarmiento Bustamante et al.
3. Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade- refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019;129(10):4451-4463.
4. Arenas DJ, Floess K, Kobrin D, et al. Increased mTOR activation in idiopathic multicentric Castleman disease. Blood. 2020;135(19):1673-1684.
5. Pierson SK, Shenoy S, Oromendia AB, et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021;5(17):3445-3456.
6. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255-2273.
7. Nishimura Y, Fajgenbaum DC, Pierson SK, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021;96(10):1241-1252.
8. Takeuchi K. Idiopathic plasmacytic lymphadenopathy: a conceptual history along with a translation of the original Japanese article published in 1980. J Clin Exp Hematop. 2022;62(2):79-84.
9. Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022;6(2):359-367.
10. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8- negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-1657.
11. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman’s disease. Am J Hematol. 2012;87(11):997-1002.
12. Cohen AB, Swaminathan A, Wang XL, et al. Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease. J Clin Oncol. 2021;39(15 suppl):7048.
13. Zhang L, Dong YJ, Peng HL, et al. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria. Lancet Reg Health West Pac. 2023;34:100720.
14. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966-974.
15. van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115-2124.
16. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti- interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627-2632.
17. Mukherjee S, Kanhai K, Kauffman D, et al. Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis. Leukemia. 2022;36(10):2539-2543.
18. Pierson SK, Khor JS, Ziglar J, et al. ACCELERATE: a patient- powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder. Cell Rep Med. 2020;1(9):100158.
19. CDC. Hospital utilization (in non-Federal short-stay hospitals). 2018. https://www.cdc.gov/nchs/fastats/hospital.htm#print. Accessed June 2023.
20. NHIS. About the National Health Interview Survey. 2019. https:// www.cdc.gov/nchs/nhis/about_nhis.htm. Accessed June 2023.
21. Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803-816.
22. Owens PL, Liang L, Barrett ML, Fingar KR. Comorbidities associated with adult inpatient stays, 2019. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville (MD), 2006.
23. Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163-175.
24. Payera E, Zofia M, Zsofia S, et al. Diagnostic and therapeutic difficulties in diffuse large B-cell lymphoma arising from HHV8 positive Castleman disease. J Hematol. 2012;1(2):65-69.
25. Sukswai N, Lyapichev K, Medeiros LJ, Khoury JD. Unusual case of human herpesvirus 8-positive large B-cell lymphoma associated with Castleman disease. Clin Case Rep. 2019;7(3):587-588.
26. Whooley M, Keirns D, Wu XX, Luker A, Silberstein PT, Hsia B. Diffuse large B-cell lymphoma in HHV8+ multicentric Castleman disease: a national analysis of demographic features. J Clin Oncol. 2023;41(16 suppl):e19535.
27. Nishikori A, Nishimura MF, Nishimura Y, et al. Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease. Int J Mol Sci. 2022;23(18):10301.
Haematologica | 109 July 2024
2206